Glover v. Cohen
Opinion
NOTE: This disposition is nonprecedential.
United States Court of Appeals for the Federal Circuit
MORRIS S. GLOVER, Plaintiff-Appellant
v.
DANIEL E. COHEN, BRUCE C. JOHNSON, CREATIVE INTEGRATION & DESIGN, INC., Defendants-Appellees
SUZANNE KAMEESE, LOWELL FRENCH, Defendants
2021-2126
Appeal from the United States District Court for the Western District of Pennsylvania in No. 2:19-cv-00734- WSH, Judge W. Scott Hardy.
Decided: October 5, 2022
MORRIS S. GLOVER, Bedford Heights, OH, pro se.
KURT JOHN NIEDERLUECKE, Fredrikson & Byron, PA, Minneapolis, MN, for defendants-appellees. Also represented by CARA S. DONELS, Des Moines, IA.
2 GLOVER v. COHEN
Before DYK, TARANTO, and STARK, Circuit Judges.
PER CURIAM.
Morris S. Glover (“Glover”) appeals the final judgment of the United States District Court for the Western District of Pennsylvania following dismissal with prejudice of his complaint, which largely concerns the prior litigation Glover v. CNS, Inc., No. 95-02227 (N.D. Ohio). For the reasons below, we affirm.
I
Glover owns expired utility and design patents, U.S.
Patent Nos. 5,466,456 (issued November 14, 1995) and D351,924 (issued October 25, 1994), which concern a facial cleanser and an ornamental design for a facial cleanser, respectively . In the current litigation, Glover appears to maintain his assertion, first made over twenty-five years ago, that his patents were infringed by a product called the Breathe Right® dilator, manufactured and sold by CNS, Inc. (“CNS”).
In 1995, Glover sued CNS in the United States District Court for the Northern District of Ohio for infringing his patents. During that litigation, one of the Defendants in the current case, Bruce C. Johnson (“Johnson”), submitted a declaration asserting that he was the primary inventor of the Breathe Right® dilator and that he had transferred his rights in the device to Creative Integration & Design, Inc. (“CID”), which in turn granted CNS an exclusive license concerning the device. Johnson maintained that Glover had nothing to do with the invention of the Breathe Right® device. Similarly, current-Defendant Daniel E. Cohen (“Cohen”), then associated with CNS, submitted a declaration that Glover had nothing to do with the Breathe Right® device. The District Court eventually granted CNS’s motion for summary judgment, finding no infringement.
GLOVER v. COHEN 3
Glover appealed, and we affirmed. See Glover v. CNS, Inc., 111 F.3d 144 (1997) (per curiam).
In the instant case, brought in 2019, Glover appears to again assert that the Breathe Right® dilator infringes his patents. He alleges that in 1987 he submitted the idea for his invention to American Idea Management Corporation (“AIM”), an entity associated with Defendants Suzanne Kameese and Lowell French. Glover contends that AIM improperly conveyed his idea to Defendant CID, which in turn improperly conveyed his idea to Defendant Johnson. He also attacks various aspects of the evidence in the prior litigation.
The caption of Glover’s Complaint indicates his claims are for “[p]atent infringement, conspiracy for a summary judgment making Plaintiff’s patents invalid,” “[d]enial of due process of law, VII Amendment to the Constitution which renders a void judgment,” and “42 U.S.C. §§ 1983, 1985, 1986.” Complaint at 1, Glover v. Cohen, No. 19-00734 (W.D. Pa. June 26, 2019). In his prayer for relief, Glover sought to void the summary judgment ruling from the prior litigation, reinstate his patents, and be provided an opportunity to demonstrate infringement in a jury trial.
Kameese, CID and Johnson, and Cohen filed three separate motions to dismiss, each of which the District Court granted. 1 Glover timely appealed. We have jurisdiction pursuant to 28 U.S.C. § 1295(a)(1).
1 Glover thereafter filed a “Motion: Objection to the Court’s ‘Memorandum Opinion,’” which the District Court construed as an untimely motion for reconsideration, but nonetheless considered and denied. See Memorandum Order denying Plaintiff’s “Motion: Objection to the Court’s Memorandum Opinion,” Glover v. Cohen, No. 19-00734 (W.D. Pa. Mar. 25, 2021).
4 GLOVER v. COHEN
II
We apply the law of the applicable regional circuit, here the Third Circuit, on issues of procedural law that do not implicate patent law, while we apply the law of our own circuit to issues of patent law. See Landmark Screens, LLC v. Morgan, Lewis, & Bockius, LLP, 676 F.3d 1354, 1361 (Fed. Cir. 2012). Thus, we apply regional circuit law to dismissals under Fed. R. Civ. P. 12(b)(6), see Endo Pharms. Inc. v. Teva Pharms. USA, Inc., 919 F.3d 1347, 1352 (Fed. Cir. 2019); applications of issue preclusion, see Voter Verified , Inc. v. Election Sys. & Software LLC, 887 F.3d 1376, 1382 (Fed. Cir. 2018); 2 and statute of limitations rulings, see id.
Like the Third Circuit, we review a pro se litigant’s submissions liberally. See Higgs v. Atty. Gen. of the U.S., 655 F.3d 333, 339 (3d Cir. 2011); In re Steed, 802 F.3d 1311, 1317 (Fed. Cir. 2015).
We apply de novo review to a Rule 12(b)(6) dismissal.
See Endo Pharms., 919 F.3d at 1352 (applying Third Circuit law). “To survive a motion to dismiss for failure to state a claim, a complaint must allege enough facts to state a claim to relief that is plausible on its face.” Id. (internal quotation marks omitted). Here, Glover failed to state any claim upon which relief could be granted.
A
Concerning patent infringement, Glover failed to state a claim upon which relief can be granted because his suit is barred by issue preclusion. Issue preclusion can be a proper basis for a Rule 12(b)(6) dismissal. See Leyse v. Bank of Am. Nat’l Ass’n, 804 F.3d 316, 320 (3d Cir. 2015).
2 Even if we were to conclude that Federal Circuit law applies to issue preclusion, the result would be the same.
GLOVER v. COHEN 5
Under this doctrine, a party cannot relitigate an issue that has already been litigated. See Peloro v. United States, 488 F.3d 163, 175 (3d Cir. 2007). That is the situation here. Glover litigated the same issue – patent infringement by the Breathe Right® dilator – in the Northern District of Ohio action and cannot relitigate that issue now.
The Third Circuit generally applies plenary review to determinations of issue preclusion. See Jean Alexander Cosmetics, Inc. v. L’Oreal USA, Inc., 458 F.3d 244, 247-49 (3d Cir. 2006) (noting abuse of discretion review for nonmutual offensive collateral estoppel). In the Third Circuit, the prerequisites for applying issue preclusion are (1) the issue sought to be precluded [is] the same as that involved in the prior action; (2) that issue [was] actually litigated; (3) it [was] determined by a final and valid judgment; and (4) the determination [was] essential to the prior judgment. . . . For defensive collateral estoppel – a form of non-mutual issue preclusion – to apply, the party to be precluded must have had a “full and fair” opportunity to litigate the issue in the first action.
Peloro, 488 F.3d at 174-75 (internal quotation marks omitted ).
Here, all of these prerequisites are met. First, the same issue – whether the Breathe Right® dilator infringes Glover’s patents – was at issue in the prior action. Second, the issue was actually litigated; the District Court expressly determined there was no infringement. Third, the issue was determined by a final and valid judgment, which was entered by the District Court and affirmed by us. Fourth, the issue was necessary to the District Court’s decision ; the Court grant of summary judgment was premised on the finding of no infringement. Finally, Glover had a full and fair opportunity to litigate and, in fact, did litigate the issue of infringement in both the District Court and this Court.
6 GLOVER v. COHEN
Because Glover is barred by the doctrine of issue preclusion from proceeding with his claim of patent infringement , we need not address any other potential deficiencies in this claim.
B
Free access — add to your briefcase to read the full text and ask questions with AI
Glover v. Cohen (Glover v. Cohen) — published by Counsel Stack Legal Research, free access to 12M+ legal documents.